ClinicalTrials.Veeva

Menu
A

Albion Finch Medical Centre | Clinical Practice of Family Medicine

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BI 456906
BI 685509
Linagliptin
Maridebart Cafraglutide
Sugar
Lebrikizumab
NN0519-0130
Glimepiride

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 9 total trials

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The st...

Enrolling
Diabetes Mellitus, Type 2
Drug: Trizepatide
Drug: NNC0519-0130

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 d...

Active, not recruiting
Obesity
Diabetes Mellitus, Type 2
Drug: Survodutide
Drug: Placebo

This study is open to adults who are at least 18 years old and have* a body mass index (BMI) of 30 kg/m² or more, or* a BMI of 27 kg/m² or more and a...

Active, not recruiting
Obesity
Drug: survodutide
Drug: Placebo

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Enrolling
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Drug: Maridebart cafraglutide
Drug: Placebo

Trial sponsors

Boehringer Ingelheim logo
Amgen logo
Merck KGaA (EMD Serono) logo
Novo Nordisk logo
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems